Table 2.
Visualization of specificity, sensitivity, and cutoff values of these 5 gene signatures as diagnostic and prognostic markers
| Clinical traits | Risk score | χ2 | P value | |
|---|---|---|---|---|
| High risk, n (%) | Low risk, n (%) | |||
| Age | 20.05 | <0.0001 | ||
| ≤60 | 86 (38.74%) | 136 (61.26%) | ||
| >60 | 161 (58.97%) | 112 (41.03%) | ||
| T | 8.085 | 0.0443 | ||
| T1 | 82 (45.30%) | 99 (54.70%) | ||
| T2 | 98 (48.52%) | 104 (51.48%) | ||
| T3 | 64 (58.72%) | 45 (41.28%) | ||
| T4 | 3 (100.00%) | 0 (0.00%) | ||
| N | 18.10 | <0.0001 | ||
| N0 | 173 (44.82%) | 213 (55.18%) | ||
| N1 | 74 (67.89%) | 35 (32.11%) | ||
| M | 0.5165 | 0.4724 | ||
| M0 | 242 (49.69%) | 245 (50.31%) | ||
| M1 | 5 (62.50%) | 3 (37.50%) | ||
| Gleason Score | 75.88 | <0.001 | ||
| 6 | 16 (35.56%) | 29 (64.44%) | ||
| 7 | 82 (33.33%) | 164 (66.67%) | ||
| 8 | 42 (66.67%) | 21 (33.33%) | ||
| 9 | 104 (75.91%) | 33 (24.09%) | ||
| 10 | 3 (75.00%) | 1 (25.00%) | ||
| New tumor event | 41.70 | <0.001 | ||
| No | 154 (41.51%) | 217 (58.49%) | ||
| Yes | 93 (75.00%) | 31 (25.00%) | ||